Updates from Phlow
Phlow and the United States Pharmacopeia have formed a strategic alliance to develop a new laboratory that will certify and validate Pharmaceutical Continuous Manufacturing processes resulting in affordable, high-quality, U.S.-manufactured essential medicines.
Business Wire | Feb. 22, 2021
This injection of additional strategic capital will further enhance Phlow’s mission to reimagine the end-to-end domestic production critical to U.S. healthcare.
Business Wire | Feb. 16, 2021
Phlow demonstrates a 100% U.S.-based and fully integrated solution that will have an extraordinary impact on the lives of patients and families for decades to come.
U.S. Representative Abigail Spanberger | Feb. 16, 2021
A unique partnership between Civica Rx, Phlow, VCU’s Medicines for All Institute, and AMPAC Fine Chemicals to ensure every American will have access to essential medicines.
Governor Ralph Northam | Jan. 21, 2021
Revolutionizing Pharma Manufacturing From The Outside In
Life Science Leader | Jan. 4, 2021
Stop Drug Shortages, Start Domestic Supply Chains
Outsourced Pharma | Nov. 10, 2020
How Phlow is revamping the way medicines are made and distributed.
CBS This Morning | Aug. 15, 2020
Phlow’s mission to reliably supply affordable, high-quality, essential medicines through U.S.-based advanced manufacturing processes.
Quartz | July 26, 2020
Phlow honored with “Inno on Fire” Award for its impact on U.S.-based pharmaceutical manufacturing of essential medicines.
American Inno | July 17, 2020
Phlow CEO Eric Edwards discusses manufacturing coronavirus treatments and other critical drugs in shortage in partnership with the U.S. government.
Fox News | May 20, 2020
Dr. Eric Edwards, CEO of Phlow Corp., joins “Squawk Alley” to discuss manufacturing essential medicines in the U.S.
CNBC | May 20, 2020
100% of Phlow team members are proud to tell others they work at Phlow.
PR Newswire | Nov. 16, 2020
Move Strengthens America’s Supply Chain and Supports COVID-19 Response.
PR Newswire | May 19, 2020
The U.S. government signed a $354 million four-year contract with new pharmaceutical company Phlow Corp. to increase American production of medications that may help treat Covid-19 in a bid to avoid potential supply chain shortages, with the potential to extend the contract to $812 million for the next ten years.
Forbes | May 19, 2020
A new Richmond-based pharmaceutical manufacturing company has received a $354 million federal contract to help build a strategic, national reserve of essential medications and to make active ingredients for more than a dozen medicines used to treat patients with COVID-19.
Richmond Times Dispatch | May 19, 2020
White House officials called the multi-million dollar contract with Virginia-based Phlow Corp. a potential landmark in returning pharmaceutical manufacture from overseas.
Washington Post | May 19, 2020